On April 1, 2022 Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported that it is scheduled to participate in the following upcoming events (Press release, Arrowhead Pharmaceuticals, APR 1, 2022, View Source [SID1234611357]):
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
31st Conference of the Asian Pacific Association for the Study of the Liver (APASL 2022) – March 30-April 3, 2022
Title: Pharmacokinetics and Safety of JNJ-73763989, an RNA Interference Therapy for Hepatitis B Virus, in Moderately Hepatically Impaired Participants
Authors: Thomas N. Kakuda, et al.
Title: Pharmacokinetics, Safety, and Tolerability of the siRNA JNJ-73763989 in Healthy Chinese Adult Participants
Authors: Haiyan Li, et al.
Title: Short interfering RNA JNJ-3989 combination therapy in chronic hepatitis B shows potent reduction of all viral markers but no correlate was identified for HBsAg reduction and baseline factors
Authors: Edward Gane, et al.
American Association for Cancer Research Annual Meeting 2022 (AACR) (Free AACR Whitepaper) – April 8-13, 2022
Title: Targeting HIF2a with siRNA: From preclinical models to the clinic
Authors: Yuanqing Ma, et al.
DIA/FDA’s Oligonucleotide-based Therapeutics Conference (Oligo22) – April 25-27, 2022
Title: Short Interfering RNA JNJ-3989 Combination Therapy
Presenter: Michael Biermer, Senior Director, Clinical Development, Janssen Pharmaceuticals
Title: ARO-HIF2 Evaluated in Clear Cell Renal Cell Carcinoma Ph1b Clinical Trial
Presenter: James Hamilton, Senior Vice President, Discovery and Translational Medicine, Arrowhead Pharmaceuticals
A copy of the presentation materials may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.